Emmanuel S. Antonarakis
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (70)
Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard model. A) The median OS in months for CTC=0 (reference), CTC+ PSMA-CTC, CTC+ PSMA+CTC but heterogeneous (
Year:
2025
Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).
Year:
2025
Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subjects at baseline, by RECIST 1.1 criteria.
Year:
2025
A. Overall Survival outcomes and B. Progression Free Survival outcomes utilizing multivariate analysis for PSMA positive CTCs, adjusting on prior treatment, risk score, CTC enumeration, comparting 3 CTC + groups with the reference group being CTC 0.
Year:
2025
Comparison of CTC enumeration and PSMA+ CTC expression in 57 baseline and paired progression samples from the PROPHECY study. All the CTC parameters (mean, median, and range) were represent in CTC/mL.
Year:
2025
The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.
Year:
2025
Purpose: Homologous recombination/DNA damage repair (HRR) alterations (HRRalt) are found in around 30% of patients with advanced prostate cancer and have been associated with worse prognosis in the metastatic castrate-resistant setting. However, there are limited data with regard to their association with outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Experimental Design: This study used a de-identified nationwide (U.S.-based) prostate cancer clinico-genomic database. Patients with de novo mHSPC treated with androgen deprivation therapy intensification with either an androgen receptor pathway inhibitor (ARPI) or a taxane who underwent tissue biopsy within 90 days of mHSPC diagnosis were included. Time to castrate resistance (TTCR) and overall survival (OS) were compared between patients with non-altered HRR and those with HRRalt in any of 14 prespecified genes per the olaparib monotherapy FDA label. TTCR and OS indexed from mHSPC diagnosis were evaluated with Cox proportional hazard models adjusted for baseline prognostic factors. Results: Of 637 eligible patients included in our analysis, 181 harbored HRRalt (28.4%). Compared with patients with non-altered HRR, those with HRRalt had less favorable TTCR when treated with an ARPI [adjusted HR (aHR) = 1.58; 95% confidence interval (CI), 1.17–2.14] or a taxane (aHR = 1.77; 95% CI, 1.3–2.4). Additionally, OS was directionally less favorable in patients with HRRalt (ARPI: aHR = 1.12; 95% CI, 0.80–1.57 and taxane: aHR = 1.23; 95% CI, 0.88–1.72). Conclusions: To date, this is the largest real-world natural history study evaluating the association of HRRalt with outcomes in the mHSPC setting. These data may inform future clinical trial design and counseling of these patients. See related commentary by Graham and Yu, p. 4001
Year:
2025
Outcomes on ARPI or taxane by CDK12alt status. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + ARPI for (A) TTCRPC and (C) OS. Outcomes for CDK12alt vs. no CDK12alt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.
Year:
2025
Outcomes on ARPI or taxane by ATMalt status. Outcomes for ATMalt vs. no ATMalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for ATMalt vs. no ATMalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.
Year:
2025
Outcomes on ARPI or taxane by BRCAalt status. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (86)
Yvette Soignier
University of Minnesota Twin Cities
Aditya Bagrodia
University of Texas Southwestern
Andrew Armstrong
Professor
Duke Cancer Institute
Ulka Vaishampayan
Professor
University of Michigan
Karim Fizazi
Université Paris-Saclay
Oliver Sartor
Tulane University School of Medicine
Ginger Milne
Professor with Tenure
Vanderbilt University Medical Center
Pedro Barata
Associate Professor of Medicine
University Hospitals Seidman Cancer Center
Laura Kotz
University of Minnesota Twin Cities
John Lozada
University of Rochester Medical Center
Benedito A. Carneiro
-
George Sledge
-
Philippa Kennedy
Faculty, Assistant Professor
University of Minnesota
Phillip Palmbos
Assistant Professor
University of Michigan Hospital
Channing Paller
Johns Hopkins University
Natalie Reizine
Assistant Professor
University of Chicago
Arul M Chinnaiyan
University of Michigan
Akhilesh Kumar
Faculty, Assistant Professor
University of Minnesota
Donald P. McDonnell
Duke University School of Medicine
Scott Tagawa
Weill Cornell Medicine
Emil Lou
University of Minnesota
Ari VanderWalde
Global Head of Clinical Trials
-
Dang Nguyen
Faculty, Assistant Professor
University of Minnesota
Young Whang
University of North Carolina at Chapel Hill School of Medicine
Eugene Shenderov
Associate Professor
Johns Hopkins University School of Medicine
Kent Mouw
Assistant Professor
Dana-Farber Cancer Institute
Haojie Huang
Professor
Mayo Clinic College of Medicine and Science
Matthew Rettig
Professor
University of California, Los Angeles
Justin Hwang
Associate Professor
University of Minnesota
Chadi Hage Chehade
Huntsman Cancer Institute
AKASH ROY
Medical University of South Carolina
Brandon Mahal
University of Miami Hospital
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Veronica Rodriguez-Bravo
Associate Professor
Mayo Clinic
Shijia Zhu
Assistant Professor
University of Minnesota
Catherine Marshall
Associate Professor
Johns Hopkins University School of Medicine
Jinhua Wang
professor
University of Minnesota System
Umang Swami
University of Utah
Rohan Garje
Clinical Associate professor
Iowa State University
Daniel J. George
Professor
Duke University
Elisabeth I. Heath
Wayne State University School of Medicine
Maha Hussain
Professor
Northwestern University
Ryan D Stephenson
Assistant Professor of Medicine
Rutgers Cancer Institute of New Jersey
Zeynep Irem Ozay
University of Utah Health Huntsman Cancer Institute
Frank Cichocki
Assistant Professor
University of Minnesota
Susan Halabi
Duke University
Heloisa Soares
Associate Professor
Huntsman Cancer Institute
Emily Egusa
University of California, San Francisco
Josep Domingo-Domenech
Professor
Mayo Clinic
Haidong Dong
Professor/Consultant
Mayo Clinic Rochester
Jacob Orme
Assistant Professor
Mayo Clinic
Scott M Dehm
Faculty, Professor
University of Minnesota
Martin Felices
Associate Professor
University of Minnesota
Xianghua Luo
Professor
University of Minnesota
Karen S Sfanos
Johns Hopkins University School of Medicine
Christopher J. Hoimes
Duke University
John Norris
Associate Research Professor
Duke University
Michael Carducci
Vice Chair, Solid Tumor Oncology
Johns Hopkins University
Carly Miller
University of Minnesota
Jonathan Chou
Assistant Professor
University of California, San Francisco
Jeffrey S Miller
University of Minnesota System
Felix Y. Feng
University of California
Mukesh Pandey
Professor of Radiology
Mayo Clinic
Angelo De Marzo
Professor
Johns Hopkins University School of Medicine
Sumit Subudhi
Assistant Professor
The University of Texas MD Anderson Cancer Center
Russell Z. Szmulewitz
Associate Professor
University of Chicago
Kevin Kelly
Professor, Associate Director of Research, SKCC
Thomas Jefferson University
Charles Nguyen
Assistant Clinical Professor
City Of Hope National Medical Center
Megan E.V. Caram
University of Michigan
Brent Rose
Associate Professor
UC San Diego Health System
Russell K. Pachynski
Washington University School of Medicine
Kathleen Storey
Assistant Professor
University of Minnesota
Nicholas Zorko
Assistant Professor
University of Minnesota
Neeraj Agarwal
Faculty Member
Dana-Farber Cancer Institute
David Nanus
Professor of Medicine
Weill Cornell Medicine
Daniel P. Petrylak
-
Tanya Dorff
Associate Professor
City Of Hope National Medical Center
Justin M. Drake
University of Minnesota
Rana R. McKay
University of California, San Diego
Samuel R. Denmeade
-
Dave Hoon
Principal Investigator
The Lundquist Institute
Xiaolei Shi
Assistant professor
University of Maryland Medical Center
Aditya Pratapa
Assistant Research Professor
Duke University
Veerabhadran Baladandayuthapani
Jeremy M.G. Taylor Collegiate Professor of Biostatistics and Chair of Department of Biostatistics
University of Michigan
R. Stephanie Huang
Faculty, Professor
University of Minnesota
Siyuan Guo
Assistant Professor
Virginia Commonwealth University
Make your next move.
Prepare your application
Review drafts before you send them.